Clinical trials
Phase 1/2 trials in Taiwan with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 10 |
| Chang Gung Memorial Hospital | 4 |
| China Medical University Hospital | 4 |
| Cytheris SA | 1 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 1 |
| NGM Biopharmaceuticals, Inc | 1 |
| National Cheng Kung University | 1 |
| National Health Research Institutes, Taiwan | 1 |
| Orient Europharma Co., Ltd. | 1 |
| SciClone Pharmaceuticals International (Cayman) Development Limited | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 3 |
| Breast Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Colorectal Neoplasms | 2 |
| Stroke | 2 |
| Acne Vulgaris | 1 |
| Ascorbic Acid Deficiency | 1 |
| Autistic Disorder | 1 |
| Breakthrough Infections | 1 |
| Bulbo-Spinal Atrophy, X-Linked | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.